Metabolic factors and blood cancers among 578,000 adults in the metabolic syndrome and cancer project (Me-Can)

Nagel, Gabriële; Stocks, Tanja; Späth, Daniela; Hjartåker, Anette; Lindkvist, Björn; Hallmans, Göran; Jonsson, Håkan; Bjørge, Tone; Manjer, Jonas; Häggström, Christel; Engeland, Anders; Ulmer, Hanno; Selmer, Randi; Concin, Hans; Stattin, Pär; Schlenk, Richard F.

doi:10.1007/s00277-012-1489-z

Cited by 40 publications

(28 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the Me-Can study, Nagel et al considered a total of 2,751 cases of myeloid and lymphoid neoplasms and their results did not support associations with mid-BP, except for a suggestion, based on a small number of cases (n = 46), for an inverse association with the risk of T-cell non-Hodgkin lymphomas in men: HR = 0.54 (0.29-1.01). 50 Lymphoid cells are closely involved in inflammatory processes and recent studies have specifically linked T-cell subtypes with vascular remodeling and the development of hypertension, 51 so there may be some mechanistic explanation, but this would need a more detailed investigation.…”

Section: Associations With the Risk Of Malignant Cancersmentioning

confidence: 99%

Blood pressure and risk of cancer in the European Prospective Investigation into Cancer and Nutrition

Christakoudi

Κακούρου

Markozannes

et al. 2019

Intl Journal of Cancer

Self Cite

View full text Add to dashboard Cite

Several studies have reported associations of hypertension with cancer, but not all results were conclusive. We examined the association of systolic (SBP) and diastolic (DBP) blood pressure with the development of incident cancer at all anatomical sites in the European Prospective Investigation into Cancer and Nutrition (EPIC). Hazard ratios (HRs) (95% confidence intervals) were estimated using multivariable Cox proportional hazards models, stratified by EPIC‐participating center and age at recruitment, and adjusted for sex, education, smoking, body mass index, physical activity, diabetes and dietary (in women also reproductive) factors. The study included 307,318 men and women, with an average follow‐up of 13.7 (standard deviation 4.4) years and 39,298 incident cancers. We confirmed the expected positive association with renal cell carcinoma: HR = 1.12 (1.08–1.17) per 10 mm Hg higher SBP and HR = 1.23 (1.14–1.32) for DBP. We additionally found positive associations for esophageal squamous cell carcinoma (SCC): HR = 1.16 (1.07–1.26) (SBP), HR = 1.31 (1.13–1.51) (DBP), weaker for head and neck cancers: HR = 1.08 (1.04–1.12) (SBP), HR = 1.09 (1.01–1.17) (DBP) and, similarly, for skin SCC, colon cancer, postmenopausal breast cancer and uterine adenocarcinoma (AC), but not for esophageal AC, lung SCC, lung AC or uterine endometroid cancer. We observed weak inverse associations of SBP with cervical SCC: HR = 0.91 (0.82–1.00) and lymphomas: HR = 0.97 (0.93–1.00). There were no consistent associations with cancers in other locations. Our results are largely compatible with published studies and support weak associations of blood pressure with cancers in specific locations and morphologies.

show abstract

Section: Associations With the Risk Of Malignant Cancersmentioning

confidence: 99%

Blood pressure and risk of cancer in the European Prospective Investigation into Cancer and Nutrition

Christakoudi

Κακούρου

Markozannes

et al. 2019

Intl Journal of Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…Interestingly, there have been plenty of studies investigating the association between MetS and cancers. MetS and/or its components have been found to be possible risk factors of several cancers, including endometrial cancer [5], [6], ovarian cancer [7], colorectal cancer [6], [8], [9], breast cancer [6], [10], lymphoma, multiple myeloma [11], thyroid cancer [12], cervical cancer [13], liver cancer [6], [14], [15], skin cancer [16], biliary tract cancer [17], pancreatic cancer [6], [18], [19], bladder cancer [6], [20] oesophageal cancer and GC [21], [22].…”

Section: Introductionmentioning

confidence: 99%

Patients with Old Age or Proximal Tumors Benefit from Metabolic Syndrome in Early Stage Gastric Cancer

et al. 2014

View full text Add to dashboard Cite

BackgroundMetabolic syndrome and/or its components have been demonstrated to be risk factors for several cancers. They are also found to influence survival in breast, colon and prostate cancer, but the prognostic value of metabolic syndrome in gastric cancer has not been investigated.MethodsClinical data and pre-treatment information of metabolic syndrome of 587 patients diagnosed with early stage gastric cancer were retrospectively collected. The associations of metabolic syndrome and/or its components with clinical characteristics and overall survival in early stage gastric cancer were analyzed.ResultsMetabolic syndrome was identified to be associated with a higher tumor cell differentiation (P = 0.036). Metabolic syndrome was also demonstrated to be a significant and independent predictor for better survival in patients aged >50 years old (P = 0.009 in multivariate analysis) or patients with proximal gastric cancer (P = 0.047 in multivariate analysis). No association was found between single metabolic syndrome component and overall survival in early stage gastric cancer. In addition, patients with hypertension might have a trend of better survival through a good control of blood pressure (P = 0.052 in univariate analysis).ConclusionsMetabolic syndrome was associated with a better tumor cell differentiation in patients with early stage gastric cancer. Moreover, metabolic syndrome was a significant and independent predictor for better survival in patients with old age or proximal tumors.

show abstract

“…TNF activates IL6 in adipose tissue and downstream of both cytokines are the NFκB and STAT3 cycles. These pathways have important roles in lymphocyte development, function and survival, and deregulation of these cycles are seen in lymphoid malignancies including DLBCL, the most common aggressive subtype examined here (26). Obesity-related lymphomagenesis is likely to be complex involving the actions of additional pro-inflammatory cytokines and immuno-modulatory mediators that trigger downstream targets that promote the clonal expansion and transformation of B cells with premalignant lesions.…”

Section: Discussionmentioning

confidence: 98%

Non-Hodgkin Lymphoma, Body Mass Index, and Cytokine Polymorphisms: A Pooled Analysis from the InterLymph Consortium

Kane

Skibola

Bracci

et al. 2015

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Background Excess adiposity has been associated with lymphomagenesis, possibly mediated by increased cytokine production causing a chronic inflammatory state. The relationship between obesity, cytokine polymorphisms and selected mature B-cell neoplasms is reported. Method Data on 4979 cases and 4752 controls from nine American/European studies from the InterLymph consortium (1988–2008) were pooled. For diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL), joint associations of body mass index (from self-reported height and weight) and 12 polymorphisms in cytokines IL1A (rs1800587), IL1B (rs16944, rs1143627), IL1RN (rs454078), IL2 (rs2069762), IL6 (rs1800795, rs1800797), IL10 (rs1800890, rs1800896), TNF (rs1800629), LTA (rs909253), and CARD15 (rs2066847) were investigated using unconditional logistic regression. BMI-polymorphism interaction effects were estimated using the relative excess risk due to interaction (RERI). Results Obesity (BMI≥30kg m−2) was associated with DLBCL risk (OR=1.33, 95%CI 1.02–1.73), as was TNF-308GA+AA (OR=1.24, 95%CI 1.07–1.44). Together, being obese and TNF-308GA+AA increased DLBCL risk almost two-fold relative to those of normal weight and TNF-308GG (OR=1.93 95%CI 1.27–2.94), with a RERI of 0.41 (95%CI −0.05,0.84, P(interaction)=0.13). For FL and CLL/SLL, no associations with obesity or TNF-308GA+AA, either singly or jointly, were observed. No evidence of interactions between obesity and the other polymorphisms were detected. Conclusions Our results suggest that cytokine polymorphisms do not generally interact with BMI to increase lymphoma risk but obesity and TNF-308GA+AA may interact to increase DLBCL risk. Impact Studies using better measures of adiposity are needed to further investigate the interactions between obesity and TNF-308G>A in the pathogenesis of lymphoma.

show abstract

Metabolic factors and blood cancers among 578,000 adults in the metabolic syndrome and cancer project (Me-Can)

Abstract: 233 35Article 2688 36 37 2 Summary 1 Background: We investigated associations between metabolic factors and blood cancer subtypes.

Cited by 40 publications

References 43 publications

Blood pressure and risk of cancer in the European Prospective Investigation into Cancer and Nutrition

Blood pressure and risk of cancer in the European Prospective Investigation into Cancer and Nutrition

Patients with Old Age or Proximal Tumors Benefit from Metabolic Syndrome in Early Stage Gastric Cancer

Non-Hodgkin Lymphoma, Body Mass Index, and Cytokine Polymorphisms: A Pooled Analysis from the InterLymph Consortium

Contact Info

Product

Resources

About